Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note released on Tuesday. The firm issued a hold rating on the medical research company’s stock.

A number of other brokerages have also recently commented on CTSO. HC Wainwright reiterated a neutral rating and issued a $1.00 target price on shares of Cytosorbents in a report on Wednesday, August 14th. EF Hutton Acquisition Co. I upgraded Cytosorbents to a strong-buy rating in a report on Monday, July 29th.

Cytosorbents Stock Performance

NASDAQ CTSO opened at $1.23 on Tuesday. The stock has a market capitalization of $66.80 million, a PE ratio of -2.10 and a beta of 0.50. The business has a 50 day simple moving average of $1.14 and a two-hundred day simple moving average of $0.98. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.12 and a quick ratio of 1.71. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $2.15.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The business had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $9.73 million. Cytosorbents had a negative return on equity of 131.84% and a negative net margin of 68.70%. During the same quarter last year, the business posted ($0.14) EPS. On average, research analysts predict that Cytosorbents will post -0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

A number of institutional investors and hedge funds have recently modified their holdings of the stock. CM Management LLC boosted its holdings in Cytosorbents by 98.8% during the 1st quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock valued at $784,000 after acquiring an additional 410,000 shares during the period. Avenir Corp boosted its holdings in Cytosorbents by 12.3% during the 4th quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock valued at $3,387,000 after acquiring an additional 334,005 shares during the period. Neuberger Berman Group LLC boosted its holdings in Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after acquiring an additional 299,103 shares during the period. Sargent Investment Group LLC boosted its holdings in Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares during the period. Finally, Key Client Fiduciary Advisors LLC boosted its holdings in Cytosorbents by 188.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 22,557 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.